ABBV · AbbVie Inc.

📣 What ABBV Says Is Next

• 2H 2026 · “Ph3 AD trials expected to begin 2H 2026; Potential approval early 2030”
  Company press release, Jun 22, 2026 · SEC filing
• this year · “AbbVie expects an approval decision later this year, which would offer adult CD patients an additional option for induction of Skyrizi.”
  Company press release, Apr 29, 2026 · SEC filing
• fourth quarter · “Provides 2026 Adjusted Diluted EPS Guidance Range of $14.37 to $14.57; Excludes Any Unfavorable Impact Related to Acquired IPR&D and Milestones Expense NORTH CHICAGO, Ill., February 4, 2026 – AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2025.”
  Company press release, Feb 4, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

• Nov 2026 · N/A · Recruiting · A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemi
  Registry primary completion date, not a results date
• Nov 2026 · N/A · Recruiting · A Study to Evaluate Folate Receptor Alpha (FRα) Expression in Adult Participants With Ovar
  Registry primary completion date, not a results date
• Dec 2026 · Phase 1 · Recruiting · A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofaci
  Registry primary completion date, not a results date
• Dec 2026 · Phase 1 · Recruiting · A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of He
  Registry primary completion date, not a results date
• Dec 2026 · Phase 3 · Active Trial · A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Parti
  Registry primary completion date, not a results date
• Jan 2027 · Phase 1 · Active Trial · Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infuse
  Registry primary completion date, not a results date

📊 Drug Pipeline

Also used in these trials (approved or third-party drugs, not ABBV's own candidates): Azacitidine, Bevacizumab, Docetaxel Anhydrous, Durvalumab, Lurbinectedin, Tremelimumab, Topotecan, Atezolizumab, Pembrolizumab, Olaparib, Oxaliplatin, Panitumumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ABBV holds $6.6B in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

• No operating cash burn in latest filings

Recent financing filings on SEC EDGAR:

• Feb 14, 2025 · Shelf registration · S-3ASR

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ABBV files for a raise →

👥 Who Owns ABBV

Share count 1,767,117,285 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.